The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1748-717X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells ; volume:4 ; number:1 ; day:22 ; month:12 ; year:2009 ; pages:1-10 ; date:12.2009
Radiation oncology ; 4, Heft 1 (22.12.2009), 1-10, 12.2009
- Urheber
-
Welsh, James W.
- Beteiligte Personen und Organisationen
-
Mahadevan, Daruka
Ellsworth, Ron
Cooke, Laurence
Bearss, David
Stea, Baldassarre
SpringerLink (Online service)
- DOI
-
10.1186/1748-717X-4-69
- URN
-
urn:nbn:de:1111-2016072612291
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Welsh, James W.
- Mahadevan, Daruka
- Ellsworth, Ron
- Cooke, Laurence
- Bearss, David
- Stea, Baldassarre
- SpringerLink (Online service)
Ähnliche Objekte (12)
Significance of c-MET tyrosine kinase domain mutations T1275I and P1300S
Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities
Correction: Thrombin receptor PAR4 cross-activates the tyrosine kinase c-met in atrial cardiomyocytes
c-Met inhibitors
Resistance to tyrosine kinase inhibitors promotes renal cancer progression through MCPIP1 tumor-suppressor downregulation and c-Met activation
Nucleic acid aptamers against the receptor tyrosine kinases C-Met and EGFR : isolation and biochemical characterization
Tyrosine kinase signaling-independent MET-targeting with CAR-T cells
Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607
Genstatus von PTEN und c-Met in Speicheldrüsenkarzinomen
Genstatus von PTEN und c-Met in Speicheldrüsenkarzinomen
In vitro effectiveness of CB469, a MET tyrosine kinase inhibitor in MET-activated cancer cells
Significance of c-MET tyrosine kinase domain mutations T1275I and P1300S
Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities
Correction: Thrombin receptor PAR4 cross-activates the tyrosine kinase c-met in atrial cardiomyocytes
c-Met inhibitors
Resistance to tyrosine kinase inhibitors promotes renal cancer progression through MCPIP1 tumor-suppressor downregulation and c-Met activation
Nucleic acid aptamers against the receptor tyrosine kinases C-Met and EGFR : isolation and biochemical characterization
Tyrosine kinase signaling-independent MET-targeting with CAR-T cells
Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607
Genstatus von PTEN und c-Met in Speicheldrüsenkarzinomen
Genstatus von PTEN und c-Met in Speicheldrüsenkarzinomen
In vitro effectiveness of CB469, a MET tyrosine kinase inhibitor in MET-activated cancer cells
Significance of c-MET tyrosine kinase domain mutations T1275I and P1300S
Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities
Correction: Thrombin receptor PAR4 cross-activates the tyrosine kinase c-met in atrial cardiomyocytes
c-Met inhibitors
Resistance to tyrosine kinase inhibitors promotes renal cancer progression through MCPIP1 tumor-suppressor downregulation and c-Met activation
Nucleic acid aptamers against the receptor tyrosine kinases C-Met and EGFR : isolation and biochemical characterization
Tyrosine kinase signaling-independent MET-targeting with CAR-T cells
Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607
Genstatus von PTEN und c-Met in Speicheldrüsenkarzinomen
Genstatus von PTEN und c-Met in Speicheldrüsenkarzinomen